RemeGen Gains NMPA Approval for Phase I/IIa Study of RC88 with Junshi Bio’s PD-1 Inhibitor
China-based pharmaceutical firm RemeGen (HKG: 9995) has received approval from the National Medical Products Administration...
Triastek Partners with Boehringer Ingelheim to Advance 3D Printed Drug Dosage Forms
China-based Triastek Inc., a leading pharmaceutical-focused 3D printing company, has entered into a partnership with...
ImmuneOnco Gains NMPA Approval for Phase Ib/II Study of IMM27M in Advanced Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...
ArkBio and Calibr Renew Collaboration to Develop First-in-Class Respiratory Drug AK0705
Shanghai Ark Biopharmaceutical Co., Ltd announced that it has renewed its co-development collaboration with Calibr,...
Agena Bioscience’s CYP2C19 Genotyping Kit Gains NMPA Approval for Cardiovascular Applications
Shanghai-based Agena Bioscience announced that its human CYP2C19 genotyping test kit, co-developed with Simcere Pharmaceutical...
Ping An Life Insurance Reports Steady Profit Growth and Expands Managed Care Services
Ping An Life Insurance Company of China Ltd released its 2022 financial report, recording RMB...
Akeso Biopharma Reports 422% Increase in Product Sales, Boosted by Cadonilimab and Penpulimab
China-based Akeso Biopharma (HKG: 9926) released its 2022 financial report, highlighting significant growth in product...
CStone Pharmaceuticals Reports 97.54% Revenue Growth in 2022, Driven by Drug Sales and Licensing Fees
China-based CStone Pharmaceuticals (HKG: 2616) released its 2022 financial report, recording total revenues of RMB...
Henlius’ OX40 Monoclonal Antibody HLX51 Gains NMPA Approval for Phase I Clinical Study
Shanghai Henlius Biotech, Inc (HKG: 2696) has announced that it has received approval from the...
Boao Lecheng and Shanghai Biomed Center Form Long-Term Partnership for Medical Innovation
The Boao Lecheng Medical Tourism Pilot Zone of Hainan Province has entered into a long-term...
Haisco Pharmaceutical’s EGFR-PROTAC HSK40118 Gains NMPA Approval for Clinical Trials
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received clinical...
Astellas Pharma’s Xtandi Gains Momentum in China with Positive Phase III ARCHES Study Results
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that its prostate cancer therapy, Xtandi (enzalutamide),...
World Orphan Drug Alliance Expands to China with RareStone Group Partnership
The World Orphan Drug Alliance (WODA) has announced its expansion to China for the first...
MabPharm Files NDA for CMAB009, Biosimilar to Erbitux, Targeting Metastatic Colorectal Cancer
Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the filing of...
Neowise Biotechnology Secures RMB 200 Million in Series A+ Financing Round
Neowise Biotechnology Co., Ltd, a T cell receptor (TCR)-therapy developer based in Suzhou, reportedly raised...
Singde Yiyang Secures Series A Financing to Expand Wellness Services in China
Singde Yiyang, a leading wellness service provider based in Qingdao, reportedly raised “hundreds of millions”...
NMPA Releases 65th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 65th batch of reference drugs for...
NHSA Launches Crackdown on Medical Insurance Fund Management with New Inspection Measures
The National Healthcare Security Administration (NHSA) is intensifying efforts to manage medical insurance funds at...
Meinian Onehealth and Astra Biotechnology Partner on Hypersensitive Blood Biomarker Detection
China-based Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a partnership with...
Immorna Enrolls First Patient in Phase I Study of JCXH-211 for Malignant Tumors
Immorna (Hangzhou) Biotechnology, an mRNA-based vaccine developer based in Hangzhou, has announced the enrollment of...